Emerging sublingual immunotherapy drugs

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 18, 2010, Pages 2963-2972

  Compalati, Enrico ^a   Rogkakou, Anthi ^a   Villa, Elisa ^a   Passalacqua, Giovanni ^a   Canonica, Giorgio Walter ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Allergic condition; Clinical development; Future perspectives; Sublingual immunotherapy

Indexed keywords

ALLERGEN; BEE VENOM; BUDESONIDE; COLECALCIFEROL; IMMUNOMODULATING AGENT; LATEX; PREDNISONE;

ADJUVANT THERAPY; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ASTHMA; ATOPIC DERMATITIS; CLINICAL TRIAL; EVIDENCE BASED MEDICINE; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; MITE; PATIENT COMPLIANCE; RESPIRATORY TRACT ALLERGY; REVIEW; SENSITIZATION; SOCIOECONOMICS; URTICARIA;

ADMINISTRATION, SUBLINGUAL; ANIMALS; HUMANS; IMMUNOTHERAPY; MEDICATION ADHERENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY HYPERSENSITIVITY;

EID: 78649242202     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.512420     Document Type: Review

References (92)

1. Bernstein DI, Wanner M, Borish L, Liss GM. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol 2001;113:1129-36
2. Aaronson DW, Gandhi TK. Incorrect allergy injections: allergists' experiences and recommendations for prevention. J Allergy Clin Immunol 2004;113:1117-21
3. Passalacqua G, Canonica GW. Sublingual immunotherapy: update 2006. Curr Opin Allergy Clin Immunol 2006;6:449-54
4. Scadding K, Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to dust mite. Clin Allergy 1986;16:483-91
5. Bousquet J, Lockey R, Malling HJ, editors. World Health Organization position paper. Allergen immunotherapy: therapeutical vaccines for allergic diseases. Allergy 1998;53(Suppl):1-33
6. Bousquet J, Van Cauwenberge P, editors. Allergic rhinits and its impact on asthma. J Allergy Clin Immunol 2001;108(5 Suppl):S146-50
7. Canonica GW, Bousquet J, Casale T, et al. Sub-lingual immunotherapy: World Allergy Organization position paper 2009. Allergy 2009;64(Suppl 91):1-59
8. Wilson DR, Torres L, Durham SR. Sublingual immunotherapy for allergic rhinitis Allergy 2005;60:3-8
9. Penagos M, Compalati E, Tarantini F, et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in children. Meta analysis of randomized controlled trials. Ann Allergy Asthma Immunol 2006;97:141-8
10. Calamita Z, Saconato H, Bronhara Pela A, et al. Efficacy of sublingual immunotherapy in asthma. Systematic review of randomized clinical trials. Allergy 2006;61:1162-72
11. Penagos M, Passalacqua G, Compalati E, et al. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest 2008;133:599-609
12. Compalati E, Penagos M, Tarantini F, et al. Specific immunotherapy for respiratory allergy: state of the art according to current meta-analyses. Ann Allergy Asthma Immunol 2009;102:22-8
13. Nieto A, Mazon A, Pamies R, et al. Sublingual immunotherapy for allergic respiratory diseases: an evaluation of meta-analyses. J Allergy Clin Immunol 2009;124:157-61
14. Compalati E, Canonica GW, Passalacqua G, et al. Considerations about the evaluation of the SLIT meta-analyses. J Allergy Clin Immunol 2010;125:509-10
15. Compalati E, Passalacqua G, Bonini M, Canonica GW. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. Allergy 2009;64:1570-9
16. Durham SR, Yang WH, Pedersen MR, et al. Sublingual immunotherapy with once-daily grass-allergen tablets: a randomised controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:802-9
17. Dahl R, Kapp A, Colombo G, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;118:434-40
18. Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007;120(6):1338-45
19. Wahn U, Tabar A, Kuna P, et al. Efficacy and safety of 5 grass pollen subllingualimmunotherapy in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009;123(1):160-6
20. Ott H, Sieber J, Brehler R, et al. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Allergy 2009;64:179-86
21. Bufe A, Eberle P, Franke-Beckmann E, et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009;123:167-73
22. Bousquet PJ, Brozek J, Bachert C, et al. The CONSORT statement checklist in allergen-specific immunotherapy: a GA2LEN paper. Allergy 2009;64:1737-45
23. Casale TB, Canonica GW, Bousquet J. Recommendations for appropriate sublingual immunotherapy clinical trials. J Allergy Clin Immunol 2009;124:665-70
24. Frew A, Powell JL, Corrigan CJ, Durham SR. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:319-25
25. Canonica GW, Baena Cagnani C, Bousquet J, et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007;62:317-24
26. Wilson AM, O'Byrne PM, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med 2004;116:338-44
27. Brozek JL, Baena Cagnani C, Canonica GW, et al. Methodology for development of the allergic rhinitis and its impact on asthma guideline 2008 update. Allergy 2008;63:38-46
28. Bousquet J, Scheinmann P, Guinnepain MT, et al. Sublingual swallow immunotherapy (SLIT) in patients with asthma due to house dust mites: a double-blind placebo-controlled study. Allergy 1999;54:249-60
29. Pajno GB, Morabito L, Barberio G, Parmiani S. Clinical and immunological effects of long-term sublingual immunotherapy in asthmatic children sensitized to mite: a double-blind study. Allergy 2000;55:842-9
30. Pajno G, Vita D, Parmiani S, et al. Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate. Clin Exp Allergy 2003;33:1641-7
31. Niu CK, Chen WY, Huang JL, et al. Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: a multicenter, double-blind, randomized, and placebo-controlled study in Taiwan. Respir Med 2006;100:1374-83
32. Lue KH, Lin YH, Sun HL, et al. Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study. Pediatr Allergy Immunol 2006;17:408-15
33. Pham-Thi N, Scheinmann P, Fadel R, et al. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures. Pediatr Allergy Immunol 2007;18:47-57
34. Stelmach I, Kaczmarek-Wozniak J, Majak P, et al. Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme in children allergic to grass pollen. Clin Exp Allergy 2009;39:401-8
35. Dahl R, Stender A, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 2006;61:185-90 (Pubitemid 43381828)
36. ClinicalTrials.gov Identifier: NCT00389363. A phase II-III trial assessing the efficacy and safety of three doses of the ALK HDM tablet in house dust mite allergic patients. Available from: http://clinicaltrials.gov/ct2/show/ NCT00389363 [Last accessed 5 May 2010]
37. Marogna M, Spadolini I, Massolo A, et al. Clinical functional and immunological effects of sublingual immunotherapy in birch allergy. J Allergy Clin Immunol 2005;115:1184-8
38. Pajno G, Passalacqua G, Vita D, et al. Sublingual immunotherapy abrogates seasonal bronchial hyperresponsiveness in children with Parietaria-induced respiratory allergy: a randomized controlled trial. Allergy 2004;59:883-7
39. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2008. Available from: http://www.ginasthma.org
40. Voltolini S, Troise C, Incorvaia C, et al. Effectiveness of high dose sublingual immunotherapy to induce a step-down of seasonal asthma: a pilot study. Curr Med Res Opin 2010;26:37-40
41. Marogna M, Spadolini I, Massolo A, et al. Long-term comparison of sublingual immunotherapy vs inhaled budesonide in patients with mild persistent asthma due to grass pollen. Ann Allergy Asthma Immunol 2009;102:69-75
42. Lombardi C, Braga M, Incorvaia C, et al. Administration regimens for sublingual immunotherapy. What do we know? Allergy 2009;64:849-54
43. Guerra L, Compalati E, Rogkakou A, et al. Randomized open comparison of the safety of SLIT in a no updosing and traditional updosing schedule in patients with parietaria allergy. Allergol Immunopathol 2006;34:82-3
44. Rodriguez F, Boquete M, Ibanez MD, et al. Once daily sublingual immunotherapy without updosing - a new treatment schedule. Int Arch Allergy Immunol 2006;140:321-6
45. Cox LS, Linnemann DL, Nolte H, et al. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 2006;117:1021-35
46. Dunsky E, Goldstein MF, Dvorin MJ, Belecanech G. Anaphylaxis due to sublingual immunotherapy. Allergy 2006;61:1235
47. Antico A, Pagani M, Crema A. Anaphylaxis by latex sublingual immunotherapy. Allergy 2006;61:1236-7
48. Eifan AO, Keles S, Bahceciler NN, Barlan IB. Anaphylaxis to multiple pollen allergen sublingual immunotherapy. Allergy 2007;62:567-8
49. de Groot H, Bijl A. Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet. Allergy 2009;64:963-4
50. Cox L. Sublingual immunotherapy in pediatric allergic rhinitis and asthma: efficacy, safety, and practical considerations. Curr Allergy Asthma Rep 2007;7:410-20
51. Agostinis F, Tellarini L, Falagiani P, et al. Safety of SLIT in very young children. Allergy 2005;60(1):133
52. Fiocchi A, Pajno G, La Grutta S, et al. Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years. Ann Allergy Asthma Immunol 2005;95:254-8
53. Di Rienzo V, Minelli M, Musarra A, et al. Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin Exp Allergy 2005;35:560-4
54. Kleine-Tebbe J, Ribel M, Herold DA. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial. Allergy 2006;61:181-4
55. Agostinis F, Foglia C, Landi M, et al. The safety of sublingual immunotherapy with one or multiple pollen allergens in children. Allergy 2008;63:1637-9
56. Lombardi C, Gargioni S, Cottini M, et al. The safety of sublingual immunotherapy with one or more allergens in adults. Allergy 2008;63:375-6
57. Marogna M, Spadolini I, Massolo A, et al. Randomized controlled open study of SLIT for respirtory allergy in real life: clinical efficacy and more. Allergy 2004;59:1205-10
58. Novembre E, Galli E, Landi F, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004;114:851-7
59. Marogna M, Tomassetti D, Bernasconi A, et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann Allergy Asthma Immunol 2008;101:206-11
60. Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect on seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007;62:943-8
61. Pajno GB, Passalacqua G, Vita D, et al. Sublingual immunotherapy abrogates seasonal bronchial hyperresponsiveness in children with Parietaria-induced respiratory allergy: a randomized controlled trial. Allergy 2004;59:883-7
62. Marogna M, Spadolini I, Massolo A, et al. Clinical, functional, and immunologic effects of sublingual immunotherapy in birch pollinosis: a 3-year randomized controlled study. J Allergy Clin Immunol 2005;115:1184-8
63. Di Rienzo V, Marcucci F, Puccinelli P, et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy 2003;33:206-10
64. Tahamiler R, Saritzali G, Canakcioglu S. Long-term efficacy of sublingual immunotherapy in patients with perennial rhinitis. Laryngoscope 2007;117:965-9
65. Durham SR, Emminger W, Kapp A, et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol 2010;125:131-8.e1-7
66. Lombardi C, Gani F, Landi M, et al. Quantitative assessment of the adherence to sublingual immunotherapy. J Allergy Clin Immunol 2004;113:1219-20
67. Passalacqua G, Musarra A, Pecora S, et al. Quantitative assessment of the compliance with a simplified SLIT regimen in real life. J Allergy Clin Immunol 2006;117:946-8
68. Passalacqua G, Musarra A, Pecora S, et al. Quantitative assessment of the compliance with once daily sublingual immunotherapy in children. Pediatr Allergy Immunol 2007;18:58-62
69. Pajno GB, Vita D, Caminiti L, et al. Children's compliance with allergen immunotherapy according to administration routes. J Allergy Clin Immunol 2005;116:1380-1
70. Roder E, Berger MY, de Groot H, Gerth van Wijk R. Sublingual immunotherapy in youngsters: adherence in a randomized clinical trial. Clin Exp Allergy 2008;38:1659-67
71. Vita D, Caminiti L, Ruggeri P, Pajno GB. Sublingual immunotherapy: adherence based on timing and monitoring control visits. Allergy 2010;65:668-9
72. Incorvaia C, Rapetti A, Scurati S, et al. Importance of patient's education in favouring compliance with sublingual immunotherapy. Allergy 2010. [Epub ahead of print]
73. Saint-Lu N, Tourdot S, Razafindratsita A, et al. Targeting the allergen to oral dendritic cells with mucoadhesive chitosan particles enhances tolerance induction. Allergy 2009;64:1003-13
74. van Hemelen D, van Oosterhout AJ. Adjuvants for immunotherapy: lost in translation? Clin Exp Allergy 2009;39:1783-5
75. van Overtvelt L, Lombardi V, Razafindratsita A, et al. IL-10-inducing adjuvants enhance sublingual immunotherapy efficacy in a murine asthma model. Int Arch Allergy Immunol 2007;145:152-62
76. Majak P, Rychlik B, Stelmach I. The effect of oral steroids with and without vitamin D3 on early efficacy of immunotherapy in asthmatic children. Clin Exp Allergy 2009;39:1830-41
77. Roder E, Berger MY, Hop WC, et al. Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care. J Allergy Clin Immunol 2007;119:892-8
78. Guez S, Vatrinet C, Fadel R, Andre C. House dust mite sublingual swallow immunotherapy in perennial rhinitis: a double blind placebo controlled study. Allergy 2000;55:369-75
79. Lima MT, Wilson D, Pitkin L, et al. Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. Clin Exp Allergy 2002;32:507-14
80. Brunetto B, Tinghino R, Braschi MC, et al. Characterization and comparison of commercially available mite extracts for in vivo diagnosis. Allergy 2010;65:184-90
81. Enrique E, Pineda F, Malek T, et al. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. J Allergy Clin Immunol 2005;116:1073-9
82. Fernandez-Rivas M, Garrido Fernandez S, Nadal JA, et al. Randomized double-blind, placebo-controlled trial of sublingual immunotherapy with a Pru p 3 quantified peach extract. Allergy 2009;64(6):876-83
83. Bussmann C, Bockenhoff A, Henke H, et al. Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis? J Allergy Clin Immunol 2006;118:1292-8
84. Pajno GB, Caminiti L, Vita D, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol 2007;120:164-70
85. Cadario G, Galluccio AG, Pezza M, et al. Sublingual immunotherapy efficacy in patients with atopic dermatitis and house dust mites sensitivity: a prospective pilot study. Curr Med Res Opin 2007;23:2503-6
86. Severino M, Cortellini G, Bonadonna P, et al. Sublingual immunotherapy for large local reactions due to honeybee sting. Double blind placebo controlled trial. J Allergy Clin Immunol 2008;122:44-8
87. Rueff F, Bilo MB, Jutel M, et al. Sublingual immunotherapy with venom is not recommended for patients with hymenoptera venom allergy. J Allergy Clin Immunol 2009;123:272-3
88. Nettis E, Colanardi MC, Soccio AL, et al. Double-blind, placebo-controlled study of sublingual immunotherapy in patients with latex-induced urticaria: a 12-month study. Br J Dermatol 2007;156:674-81
89. Bernardini R, Campodonico P, Burastero S, et al. Sublingual immunotherapy with a latex extract in paediatric patients: a double-blind, placebo-controlled study. Curr Med Res Opin 2006;22:1515-22
90. Bernardini R, Pecora S, Milani M, Burastero SE. Natural rubber latex allergy in children: clinical and immunological effects of 3-years sublingual immunotherapy. Eur Ann Allergy Clin Immunol 2008;40:142-5
91. Roelofs-Haarhuis K, Wu X, Gleichmann E. Oral tolerance to nickel requires CD4+ invariant NKT cells for the infectious spread of tolerance and the induction of specific regulatory T cells. J Immunol 2004;173:1043-50
92. Incorvaia C, Mauro M, Cappelletti T, et al. New applications for sublingual immunotherapy in allergy. Recent Pat Inflamm Allergy Drug Discov 2009;3:113-17